Related Experiment Videos
Hormonal therapy for stomach cancer.
1Department of Surgery, Veterans General Hospital-Taipei, Taiwan, Republic of China.
Medical Hypotheses
|October 1, 1992
Summary
Gastric cancer patients with estrogen receptors (ER) and c-erbB-2 gene expression may benefit from estrogen therapy. This approach could be more effective than tamoxifen for these specific stomach cancer cases.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Stomach cancer is a leading cancer in Asia, with limited treatment efficacy for radiation and chemotherapy.
- Hormonal therapy, including tamoxifen, has shown conflicting results in gastric cancer treatment.
- Estrogen receptors (ER) are found in 50% of Chinese gastric cancer patients, and c-erbB-2 oncogene amplification is linked to cancer advancement.
Purpose of the Study:
- To investigate the potential benefit of estrogen therapy in ER-positive gastric cancer patients.
- To explore the hypothesis that estrogen inhibits c-erbB-2 expression via ER in gastric cancer cells, similar to breast cancer.
Main Methods:
- Analysis of estrogen receptor (ER) presence in gastric cancer tissues.
- Assessment of c-erbB-2 oncogene amplification and overexpression.
- Review of existing literature on hormonal therapies and c-erbB-2 in various cancers.
Main Results:
- Estrogen receptors (ER) are present in a significant proportion of gastric cancer cases.
- c-erbB-2 oncogene amplification and overexpression correlate with advanced gastric cancer.
- Estrogen's inhibitory effect on c-erbB-2 via ER observed in breast cancer cell lines suggests a potential mechanism for gastric cancer.
Conclusions:
- Patients with ER-positive and c-erbB-2-positive gastric tumors may respond better to estrogen therapy than tamoxifen.
- Estrogen therapy could represent a novel treatment strategy for a subset of gastric cancer patients.
- Further clinical studies are warranted to validate the efficacy of estrogen therapy in this specific patient group.